CompletedNCT05455684
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
This study evaluated the safety and effectiveness of Aticaprant for people with depression.
Medication studyAges 18–74Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Aticaprant for people with depression.
Who was this study for?
Listed age limits: 18 years to 74 years.
- Listed locations
- Tucson and 119 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: June 22, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 513
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, Belgium, ...
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT05455684
- Official title
Show the full official title
A Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Get this study by email
Recruitment & locations
CompletedTucson, United States · Anaheim, United States · Culver City, United States
95 more locations
- Glendale, United States
- Long Beach, United States
- Oceanside, United States
- Santa Ana, United States
- Temecula, United States
- Farmington, United States
- Clearwater, United States
- Clermont, United States
- Fort Myers, United States
- Hialeah, United States
- Miami, United States
- Miami Gardens, United States
- Miami Lakes, United States
- Orange City, United States
- Tampa, United States
- Berwyn, United States
- Chicago, United States
- Kansas City, United States
- Monroe, United States
- Methuen, United States
- O'Fallon, United States
- Mount Kisco, United States
- New York, United States
- Rochester, United States
- The Bronx, United States
- Cincinnati, United States
- Dayton, United States
- Garfield Heights, United States
- Media, United States
- Philadelphia, United States
- Bellaire, United States
- Fort Worth, United States
- Friendswood, United States
- Houston, United States
- Clinton, United States
- Charlottesville, United States
- Bellevue, United States
- Buenos Aires, Argentina
- Ciudad Autonoma Buenos Aires, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- Mendoza, Argentina
- Rosario, Argentina
- Frankston, Australia
- Melbourne, Australia
- Alken, Belgium
- Brussels, Belgium
- Duffel, Belgium
- Sint-Niklaas, Belgium
- Fortaleza, Brazil
- Goiânia, Brazil
- Porto Alegre, Brazil
- Rio de Janeiro, Brazil
- São Bernardo do Campo, Brazil
- São José do Rio Preto, Brazil
- São Paulo, Brazil
- Cherven Bryag, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Veliko Tarnovo, Bulgaria
- Klecany, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Ústí nad Labem, Czechia
- Budapest, Hungary
- Gyöngyös, Hungary
- Kalocsa, Hungary
- Pécs, Hungary
- Szekszárd, Hungary
- Bergamo, Italy
- Catanzaro, Italy
- Lecce, Italy
- Milan, Italy
- Siena, Italy
- Bełchatów, Poland
- Bialystok, Poland
- Gdansk, Poland
- Lodz, Poland
- Poznan, Poland
- Torun, Poland
- Braga, Portugal
- Lisbon, Portugal
- Barcelona, Spain
- Madrid, Spain
- Málaga, Spain
- Palma de Mallorca, Spain
- Ponferrada, Spain
- Sabadell, Spain
- Vigo, Spain
- Vitoria-Gasteiz, Spain
- Gothenburg, Sweden
- Lund, Sweden
- Stockholm, Sweden
- Czechia
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Aticaprant for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Aticaprant.
Who was this study for?
Listed age limits: 18 years to 74 years.
